Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4Ticker(s): LOXO, EXEL, RXDX, NVS
An oncologist with clinical experience in treating TRK fusion cancers with at least one of the available multikinase/TRK inhibitors.
Please describe your clinical experience and the patient demographics who suffer from TRK fusion cancers.Added By: c_admin
Out of all the 55 patients enrolled in LOXO’s 101 trials, 22% had either stagnated or progression in the disease, and in 76% of the patients tumor reduction in size was observed. 12% of the patients had complete response rate. 6 patients responded to larotrectinib but subsequently progressed. What's your opinion of this data and how likely would you be to make a switch from other treatment options?
Have you used Cabozantinib (Cabometyx) in your clinical practice, since its FDA approval in April 2016? What is the first line of treatment, when you need to use a TRK inhibitor drug? Have you been using midostaurin, crizotinib, entrectinib or regorafenib, and what has been your experience with them?Added By: c_admin
The FDA’s Pediatric Subcommittee granted its support for larotrectinib after observing its effects in a phase I trial enrolling patients 1 to 21 years of age. Are there bigger safety concerns regarding risk and adverse effects in this patient population?Added By: c_admin
On a scale from 1-10, with 10 being very excited, how would you rate your level of excitement for this drug if approved?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.